Financial Highlights
- Revenue for the year to 30 June 2022 of £0.05m (2021: £0.69m)
- Loss for the year of £4.7m (2021: loss of £0.7m)
- R&D spend of £3.9m (2021: £4.5m)
- Debt free and cash at bank of £4.6m (2021: £2.6m)
Operational Highlights
- JAMA Pediatrics’ PALOH (Pharmacogenetics to Avoid Loss of Hearing) paper published to support the implementation of the Genedrive® MT-RNR1 test in the Neonatal Intensive Care setting
- First NHS Deployments and sales of the Genedrive® System for Antibiotic Induced Hearing Loss at Manchester Hospitals
- Launched 2nd generation Genedrive® system to support strategy focus of assay development to emergency care settings
- NICE accelerated evaluation of the Genedrive® MT-RNR1 ID test
- NICE includes Genedrive® CYP2C19 ID Kit in Diagnostics Assessment Programme
- Point-of-Care Genedrive® COV19-ID Kit received Coronavirus Test Device Approval (“CTDA”)
- New product development programme initiated for use of Genedrive® Point-of-Care device for ischemic stroke treatment in emergency care settings
- Filed US FDA Pre-submission for the Genedrive® MT-RNR1 ID product range
David Budd, CEO of genedrive plc, said: The Company has made good progress on advancing our strategy in pharmacogenetics, and the opportunity to be leaders in the establishment of genetic testing in acute point of care. Our Genedrive system delivers unambiguous clinically actionable information on the wards by nurses with no previous experience in molecular testing, making a positive impact on health outcomes. Market development and engagement is positive and growing, as we have unique products with a positive health economic and clinical outcome.”
